Clinical trials: Adult Depression
Depression
Combination Lexapro and Massage for Treatment of Depression in Older Adults
Depression is a common and disabling condition which represents a substantial public health concern, especially with the aging of the population in general.
- Trial name
- NCT00643162
- Testing
- Lexapro, Light touch, Massage
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Cedars-Sinai Medical Center
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
The primary objective of this study is to evaluate the long-term safety of desvenlafaxine succinate sustained release tablets during 10-month open-label treatment of Japanese subjects with major depressive disorder (MDD).
- Trial name
- NCT00831415
- Testing
- desvenlafaxine succinate sustained release tablets
- Where
- 17 sites in Japan
- Volunteers
- 304 people
- Sponsor
- Pfizer
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Cardiorespiratory Failure
Mobile Coping Skills Training to Improve Cardiorespiratory Failure Survivors' Psychological Distress
This is a pilot randomized clinical trial involving adult survivors of cardiorespiratory failure treated in intensive care units (ICUs) that is designed to test the acceptability, feasibility, and clinical impact of a coping…
- Trial name
- Blueprint (NCT04329702)
- Testing
- Coping skills training mobile app with call from CST therapist, Coping skills training mobile app only
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
A multicenter, 8-week study to evaluate the efficacy of 2 doses (50 and 100 mg/day) of desvenlafaxine succinate sustained-release (DVS SR) versus placebo in adult outpatients with major depressive disorder.
- Trial name
- NCT01432457
- Testing
- desvenlafaxine succinate sustained-release 50 mg/day, desvenlafaxine succinate sustained-release 100 mg/day
- Where
- 61 sites in United States
- Volunteers
- 924 people
- Sponsor
- Pfizer
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Back Pain Lower Back Chronic
MOTIVATE: Moving to Improve Outcomes for Older Adults
The overarching goal of this study is to evaluate a tele-based behavioral change intervention for older adults (aged 50 years and older) with chronic low back pain (cLBP) and comorbid depression, and to ultimately assess its…
- Trial name
- NCT03914469
- Testing
- Behavioral Intervention Group
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Texas Southwestern Medical Center
Treatment Resistant Depression, Refractory Depression
Ketamine for Older Adults Pilot
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD).
- Conditions
- Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression
- Trial name
- NCT04504175
- Testing
- Ketamine
- Where
- 5 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Down Syndrome, Depression
Fluoxetine Treatment of Depression in Down Syndrome
The purpose of the study is to do a preliminary assessment of whether fluoxetine is effective, safe, and tolerable for the treatment of depression in adults with Down syndrome.
- Trial name
- NCT05458479
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
ANC-501 in the Treatment of Adults With Major Depressive Disorder
A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder
- Trial name
- NCT05439603
- Testing
- ANC-501
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Depressive Symptoms
A Systems-Level Intervention for Rural Adults With Depression
This study aims to test the effectiveness of a computer-assisted cognitive behavioral therapy for depression among rural adults.
- Trial name
- NCT04502186
- Testing
- Raising Our Spirits Together, Enhanced Control Condition
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of Michigan
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Sickle Cell Disease, Depression
Designing an Implementation Strategy for Delivering Routine Mental Health Screening and Treatment
African Americans living with chronic health conditions are more likely to experience depression and other mental health disorders than their healthy counterparts, and are more likely to experience severe depression than whites…
- Conditions
- Sickle Cell Disease, Depression, Anxiety
- Trial name
- NCT04587661
- Testing
- off-the-shelf digital CBT, adapted digital CBT
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Pittsburgh
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
- Trial name
- NCT00384033
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR), Duloxetine 60 mg/day
- Where
- 22 sites in United States
- Volunteers
- 638 people
- Sponsor
- Pfizer
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436149
- Testing
- SPD489 (Lisdexamfetamine dimesylate )
- Where
- 85 sites in United States, Canada and 4 more
- Volunteers
- 1,262 people
- Sponsor
- Shire
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT02196506
- Testing
- Brexpiprazole +ADT
- Where
- 47 sites in United States, Germany and 3 more
- Volunteers
- 837 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.